Actualités et communiqués de presse Biomx 2026 | PHGE | ISIN US09090D5095

Actualités Eulerpool Biomx

Actualités de l'action Biomx

Biomx est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Biomx.

12 février·
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
10 février·
ChartMill
Top stock movements in today's session.
10 février·
ChartMill
Here are the top movers in Tuesday's session.
28 janvier·
Benzinga
What's Driving the Market Sentiment Around BiomX Inc?
27 janvier·
Benzinga
BiomX Shares Halted On Circuit Breaker To The Upside, Stock Now Up 82.68%
27 janvier·
Benzinga
BiomX Shares Resume Trade
29 décembre·
Yahoo
BiomX Announces $3.0 Million Private Placement
29 décembre·
Benzinga
BiomX Commences ~$3M Private Placement Of Series Y Convertible Preferred Stock
8 décembre·
Benzinga
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump
8 décembre·
Benzinga
US Stocks Mixed; Dow Falls Over 100 Points
26 novembre·
Benzinga
HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $26 Price Target
25 novembre·
Benzinga
BiomX Announced That The U.S. FDA Is Continuing Its Evaluation Of The Nebulizer Device Used For Drug Administration In The Co's Phase 2b Trial Of BX004 In Patients With Cystic Fibrosis; Following The DMC Review, The Study Protocol Will Be Updated, And Topline Results Are Now Expected In Q2 2026
14 novembre·
Yahoo
BiomX Inc. Announces 1-for-19 Reverse Stock Split
12 novembre·
SeekingAlpha
BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript
4 septembre·
Yahoo
BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
13 août·
SeekingAlpha
BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript
12 août·
Benzinga
What to Expect from BiomX's Earnings
14 juillet·
Yahoo
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
14 juillet·
Benzinga
BiomX Initiates Phase 2b Trial With First Patient Dosed In BX004 Program For Cystic Fibrosis
18 juin·
Benzinga
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket

Communiqués de presse relatifs à l'action Biomx

Biomx publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

10 août•
Biomx
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update
7 août•
Biomx
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022
4 août•
Biomx
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
6 juillet•
Biomx
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
28 juin•
Biomx
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
27 juin•
Biomx
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
24 mai•
Biomx
BiomX Announces Corporate Restructuring
20 mai•
Biomx
BiomX Announces Publication in the Journal, Bioinformatics
11 mai•
Biomx
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update
6 mai•
Biomx
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients
5 mai•
Biomx
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
30 mars•
Biomx
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
23 mars•
Biomx
BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022
24 février•
Biomx
BiomX Presenting at Three Upcoming Investor Conferences
4 janvier•
Biomx
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
17 novembre•
Biomx
BiomX Presenting at Two Upcoming Conferences in November
15 novembre•
Biomx
BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update
9 novembre•
Biomx
BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021
18 octobre•
Biomx
BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study
13 octobre•
Biomx
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
2 septembre•
Biomx
BiomX to Present at Upcoming September Investor Conferences
16 août•
Biomx
BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update
12 août•
Biomx
BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021
26 juillet•
Biomx
BiomX Inc. Announces $15 Million Registered Direct Offering
14 juin•
Biomx
BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages
9 juin•
Biomx
BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference
24 mai•
Biomx
BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates
18 mai•
Biomx
BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease
18 mai•
Biomx
BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021
20 avril•
Biomx
BiomX to Present at Upcoming April Investor Events

Biomx News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Biomx (PHGE, ISIN : US09090D5095). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Biomx.